Pharmaceutical Research

, Volume 15, Issue 2, pp 175–187

DNA Methylation as a Target for Drug Design

  • Christina M. Bender
  • Jean-Marc Zingg
  • Peter A. Jones
Article

DOI: 10.1023/A:1011946030404

Cite this article as:
Bender, C.M., Zingg, JM. & Jones, P.A. Pharm Res (1998) 15: 175. doi:10.1023/A:1011946030404

Abstract

DNA methylation is essential for normal embryonic development. Distinctive genomic methylation patterns must be formed and maintained with high fidelity to ensure the inactivities of specific promoters during development. The mutagenic and epigenetic aspects of DNA methylation are especially interesting because they may lead to the inactivation of genes which are involved in human carcinogenesis. The mutagenicity of 5-Methylcytosine (5mC) and the role of promoter hypermethylation in gene silencing, particularly in cancer, suggest a clinical significance for the design of novel DNA methylation inhibitors which may be utilized to reverse the effects of DNA methylation.

DNA methylation5-Methylcytosinecancer5-Aza-2′-deoxycytidine

Copyright information

© Plenum Publishing Corporation 1998

Authors and Affiliations

  • Christina M. Bender
  • Jean-Marc Zingg
  • Peter A. Jones
    • 1
  1. 1.Urologic Cancer Research LaboratoryUSC/Norris Comprehensive Cancer Center, University of Southern California School of MedicineLos Angeles